Therakos acquired by CVC Capital Partners

CVC Capital Partners, a Luxembourg-based private equity and investment advisory firm, completed the acquisition of Therakos business of Mallinckrodt Pharmaceuticals, a global specialty pharmaceutical company, for $925m. You can submit deals you were involved with here: https://lnkd.in/d_Firwmh "Today's announcement underscores our commitment to executing on our strategic priorities and creating value for our stakeholders. This transaction provides the Therakos business with an ideal partner to invest in its continued growth, and we look forward to closely working with CVC to transition Therakos for the benefit of patients, healthcare providers, partners and employees. I thank the Therakos team for their ongoing commitment and dedication to improving the lives of patients," Siggi Olafsson, Mallinckrodt President and CEO. CVC Capital Partners was advised by Candesic, PwC, UBS and Freshfields (led by Neal J Reenan and Ian Bushner). Mallinckrodt (led by Siggi Olafsson and Bryan Reasons) as advised by Lazard, A&O Shearman (led by Gillian Holgate), Arthur Cox LLP, Wachtell, Lipton, Rosen & Katz (led by Victor Goldfeld) and Joele Frank (led by Michael Freitag). #MergersAcquisitionsDivestitures #PrivateEquity #Pharmaceutical

Join for the upcoming LSX webinar 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐄𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐏𝐡𝐚𝐫𝐦𝐚 𝐌&𝐀 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞: 𝐓𝐫𝐞𝐧𝐝𝐬, 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬, 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 next Wednesday, 23 October, 3-4pm (UK) 10-11am (ET), with Oliver Barnes (Financial Times), Konstantina Katcheves (Teva Pharmaceuticals), Corey Brown (Foley Hoag LLP), Michelle Li (Bristol Myers Squibb). We will discuss the latest trends driving M&A activity in the pharmaceutical sector, as well as the challenges and opportunities that come with it. From navigating regulatory hurdles to unlocking value post-acquisition. Apposite Capital has backed Kelso Pharma led by Thomas Stratford to build a European Specialty Pharma platform. Since inception Kelso acquired two specialty pharma companies and in-licensed several new products. 𝐉𝐨𝐢𝐧 𝐡𝐞𝐫𝐞: https://lnkd.in/ejGZ9D3R #Pharma #MandA #Healthcare #BusinessDevelopment #Pharmaceuticals Apposite Capital Kelso Pharma

Oncimmune's commercial traction with 'big pharma' puts it on track to hit revenue target @OncimmuneECDT #AIM #ONC. Oncimmune Holdings PLC (AIM:ONC) said it is increasingly confident it will hit its annual revenue target of £6.9 million, supported by a growing number of high-value contracts and strong demand from major pharmaceutical clients. Since early September, Oncimmune has added three new agreements worth £340,000, building on a quarter marked by eight new deals totalling £2.14 million. Two of the latest agreements involve new research areas for an existing top 10 global pharmaceutical client, underscoring Oncimmune’s success in attracting repeat business... http://ow.ly/r89l105NukZ

Alliance Pharmaceuticals Limited agrees terms for take private by DBAY Advisors #consumerhealthcare Edmond de Rothschild Asset Management Deutsche Numis Evercore Investec Slaughter and May Travers Smith https://lnkd.in/ezyq7wUG

Royalty Pharma, a company specializing in acquiring pharmaceutical royalties, and Pharmakon Advisors, LP, an investment manager providing non-dilutive debt for the life sciences industry, completed the $375m investment in Geron Corporation, a commercial-stage biopharmaceutical company. You can submit deals you were involved with here: https://lnkd.in/d_Firwmh “The substantial financial commitment of exceptional long-term partners like Royalty Pharma and Pharmakon Advisors strengthens our cash position and further solidifies our balance sheet, while providing flexibility to invest in our future. We believe that the terms reflect the significant commercial potential of RYTELO. The proceeds are expected to enable us to support the commercial launch of RYTELO in the U.S. and potential launch in the EU, complete our Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis, invest in supply chain redundancy for RYTELO, and our general working capital requirements,” Michelle Robertson, Geron Executive Vice President and CFO. Geron was advised by TD Cowen and Cooley LLP. Royalty Pharma was advised by Fenwick & West and Goodwin. Pharmakon Advisors was advised by Akin Gump Strauss Hauer & Feld LLP. #MergersAcquisitionsDivestitures #Pharmaeutical #Biopharmaceutical

A Weil team led by Private Funds partners James Sargent, Peter Boulle and Sophie Smith and Tax partners Aron Joy and Andrew Morris advised Gyrus Capital, a European investment firm dedicated to transformational investments in the healthcare and sustainability sectors, on the closing of a €600m single-asset continuation vehicle for Essential Pharma, an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas. The continuation vehicle was led by AlpInvest. Read more about this deal and view the full Weil team: https://lnkd.in/e2bNwPwQ

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, agreed to acquire Ironshore, a pharmaceutical company that markets and distributes Jornay PM, for $550m. “The Ironshore acquisition is a unique opportunity to deliver a transaction that is immediately accretive to Collegium while meeting all of our strategic objectives through the addition of a growing commercial asset that diversifies our portfolio, has significant revenue potential and exclusivity into the 2030s. The addition of Jornay PM will establish a new presence for Collegium in ADHD, a large and growing market, where we can leverage our core commercial competencies and proven commercial execution capabilities to maximize the brand’s potential. Our healthy balance sheet and strong financial position enabled us to secure attractive financing for the transaction with terms that reduce our cost of capital and enhance our flexibility in the management of our debt," Michael Heffernan, Collegium Chairman and Interim President and CEO. Ironshore (led by Stephanie Read) is advised by Centerview Partners, Cleary Gottlieb Steen & Hamilton LLP and Goodwin Procter. Collegium (led by Michael Heffernan) is advised by Lazard and Hogan Lovells. #MergersAcquisitionsDivestitures #Healthcare #Pharmaceuticals

Transforming Healthcare: Novo Holdings’ Game-Changing Acquisition Novo Holdings, the majority shareholder of Novo Nordisk A/S, has received European Union approval for its landmark acquisition of Catalent Inc. (NYSE: CTLT), a leading U.S. contract drug manufacturer. This $16.5 billion deal is set to revolutionize pharmaceutical manufacturing, boosting production capacity for innovative treatments like Novo Nordisk’s Wegovy, a groundbreaking weight-loss therapy. As part of the acquisition, three advanced fill-finish facilities in Italy, Belgium, and the U.S. were transferred to Novo Nordisk. These facilities will play a critical role in addressing supply chain constraints and meeting the soaring demand for GLP-1 weight-loss drugs. This strategic investment not only strengthens Novo Holdings’ position in the industry but also underscores its commitment to delivering scalable and innovative healthcare solutions globally. 🌍 A brighter future for patients worldwide is on the horizon! #TransformingHealthcare #PharmaceuticalInnovation #NovoHoldings #Catalent #Wegovy #MergersAndAcquisitions

Our Annual Report is fresh off the press! Grünenthal's people have transformed our company over the last few years, uniquely positioning us to meet the increased demand for better pain treatments. 🌎 Our medicines today help more patients than ever before as we are growing our footprint in key pharmaceutical markets, especially in the United States 🧬 We advanced key R&D projects, creating one of the strongest pain-focused pipelines in the industry 📦 We ensured uninterrupted supply of medicines to patients in over 100 countries 💊 Through strategic acquisitions, we expanded our portfolio of established medicines This momentum put us in an excellent position to deliver outstanding business performance.  Read more about our story of transformation in our Annual Report: https://bit.ly/3UklN84 #WeAreGrünenthal #WorldFreeofPain

ANI Pharmaceuticals President and CEO, Nikhil Lalwani, and our CFO, Stephen Carey, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 3pm EST in NYC. For details and webcast information, see our press release in the comments below. #ANIP #pharmaceuticals #investors